Twist Bioscience通过双特异性许可协议扩展抗体发现服务-动脉网

Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement

PHARMA FOCUS ASIA 等信源发布 2026-02-18 17:30



可切换为仅中文







Twist Bioscience Corporation, a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement with Invenra Inc. (“Invenra”), a company that has developed platform technologies to discover therapeutic antibody candidates. Under the terms of the agreement, Twist will become the co-exclusive provider, together with Invenra, of Invenra’s B-Body® bispecific antibody platform (“B-Body platform”), extending Twist’s antibody discovery services..

Twist Bioscience Corporation是一家中型成长与价值并重的生物技术公司，今天宣布已与Invenra Inc.（“Invenra”）达成许可协议。Invenra是一家开发了用于发现治疗性抗体候选物的平台技术的公司。根据协议条款，Twist将与Invenra共同成为Invenra的B-Body®双特异性抗体平台（“B-Body平台”）的共同独家供应商，从而扩展Twist的抗体发现服务。

“Bispecific antibodies have emerged as one of the most promising therapeutic modalities, validated both clinically and commercially, with the ability to unlock new mechanisms of action. This is exemplified in that the development of this class of biological therapeutic is growing at an accelerated pace compared to more standard monospecific approaches,” said Emily M.

“双特异性抗体已成为最有前途的治疗方式之一，其临床和商业价值都得到了验证，能够解锁新的作用机制。这一点的例证是，与更为标准的单特异性方法相比，这类生物治疗药物的开发正在以加速的速度增长，”Emily M.表示。

Leproust, CEO and co-founder of Twist Bioscience. “Licensing the B-Body platform gives us direct access to a proven and scalable bispecific antibody platform that complements our current service offerings and further solidifies our position at the forefront of enabling next-generation biologics discovery for our customers, whether through traditional methods or AI-enabled.”.

Twist Bioscience首席执行官兼联合创始人Leproust表示：“获得B-Body平台的许可使我们能够直接使用一个经过验证且可扩展的双特异性抗体平台，该平台补充了我们目前的服务，并进一步巩固了我们在为客户推动下一代生物药物发现方面的前沿地位，无论是通过传统方法还是人工智能辅助的方式。”

The B-Body platform expands and complements Twist’s current antibody discovery services as well as giving customers the plug-and-play flexibility to utilize their own pre-existing monospecific antibodies in the B-Body platform. With a comprehensive offering spanning in vivo, in vitro and AI-enabled discovery methods combined with high throughput antibody expression and characterization capabilities, and now adding on a powerful bispecific technology, Twist meets customers’ needs whether they are utilizing Twist’s biologics discovery capabilities, using Twist as a wet lab partner or training a large language model (LLM)..

B-Body平台扩展并补充了Twist当前的抗体发现服务，同时为客户提供了即插即用的灵活性，使其能够在B-Body平台上利用自己已有的单特异性抗体。通过全面的服务覆盖体内、体外和人工智能驱动的发现方法，并结合高通量抗体表达和表征能力，如今又增加了一项强大的双特异性技术，Twist能够满足客户的需求，无论他们是在利用Twist的生物制剂发现能力，将Twist作为湿实验室合作伙伴，还是训练大型语言模型（LLM）。

“The B-Body platform is designed to overcome multiple challenges commonly faced by bispecifics by enabling extremely favorable and predictable developability characteristics as well as at high concentrations with low viscosity needed for subcutaneous delivery,” said Roland Green, Ph.D., CEO and chairman of Invenra.

“B-Body平台旨在通过实现极为优越且可预测的开发特性，以及满足皮下注射所需的高浓度和低粘度，来克服双特异性抗体通常面临的多重挑战。” Invenra公司首席执行官兼董事长Roland Green博士说道。

“By licensing our B-Body technology to Twist, we leverage their expertise and infrastructure to enable broad access to the platform to support the rapidly growing demand for the development of next-generation bispecifics that address unmet medical needs for a breadth of diseases.”.

“通过将我们的B-Body技术授权给Twist，我们利用他们的专业知识和基础设施，使平台能够广泛获取，以支持下一代双特异性抗体的开发需求快速增长，从而满足多种疾病未被满足的医疗需求。”

Twist will provide Invenra with an upfront payment of $5 million in cash and $15 million in Twist common stock. In a secondary transaction, Twist is taking an approximately 6% ownership position in Invenra through a preferred stock purchase from existing Invenra stockholders for $13.8 million in Twist common stock.

Twist将向Invenra提供500万美元的现金预付款和1500万美元的Twist普通股。在一项二级交易中，Twist将通过从现有Invenra股东手中购买优先股，以1380万美元的Twist普通股获得Invenra约6%的股权。

Twist receives all revenue generated for bispecific antibody discovery services conducted by Twist as well as all license revenue, whether signed by Invenra or Twist. Twist will pay Invenra a 20% royalty on all license revenue..

Twist获得由其进行的双特异性抗体发现服务所产生的所有收入以及所有许可收入，无论这些许可是由Invenra还是Twist签署的。Twist将向Invenra支付所有许可收入的20%作为版税。

Conference Call Information

电话会议信息

The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today. The conference call will be webcast live through the Investor Relations section under the “Company” tab at www.twistbioscience.com. Those parties interested in participating via telephone must register on the Company’s Investor Relations website or by clicking here.

公司计划于今天东部时间上午8:00举行分析师和投资者电话会议及现场音频网络广播。电话会议将通过www.twistbioscience.com网站“公司”标签下的投资者关系部分进行现场直播。有兴趣通过电话参与的各方必须在公司的投资者关系网站上注册，或者点击这里注册。

Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast replay will be available for two weeks in the Investor Relations section at www.twistbioscience.com..

注册后，所有电话参与者将收到拨入号码以及用于接入电话的唯一PIN码。为避免延误，我们鼓励参与者在预定开始时间前十五分钟拨入电话会议。网络广播重播将在www.twistbioscience.com的投资者关系部分提供两周。

About Twist Bioscience Corporation

关于Twist Bioscience公司

At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and defense, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet.

在 Twist Bioscience，我们为那些正在让世界变得更好的客户服务。在医学、农业、工业化学品和国防等领域，我们的客户通过使用我们的合成 DNA 工具，正在开发改善生活和提高地球可持续性的方法。

The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts..

我们的客户越快取得成功，对我们所有人都越好，而Twist Bioscience具备独特的优势，能够帮助加速他们的努力。

Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead.

我们的创新硅基DNA合成平台为客户提供前所未有的精准度。我们的平台技术克服了低效问题，实现了经济高效、快速、精准、高通量的合成、测序及治疗发现，提供客户所需的工具质量和数量，助其迅速把握未来机遇。

For more information about our products and services, please visit www.twistbioscience.com..

有关我们的产品和服务的更多信息，请访问 www.twistbioscience.com。

在LinkedIn | X | YouTube | Instagram | Bluesky上关注我们

Twist Bioscience Legal Notice Regarding Forward-Looking Statements

Twist Bioscience 关于前瞻性声明的法律声明

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, statements regarding the ability to utilize the B-Body platform to expand service offerings and meet future demand for bispecific therapeutics.

本新闻稿包含前瞻性陈述。除本文所含历史事实陈述之外的所有陈述均为前瞻性陈述，反映了管理层根据《1995年私人证券诉讼改革法案》的安全港条款作出的当前信念和期望，包括关于利用B-Body平台扩大服务范围并满足未来双特异性治疗需求的陈述。

Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.

前瞻性声明涉及已知和未知的风险、不确定性以及其他重要因素，这些因素可能导致Twist的实际结果、表现或成就与前瞻性声明中明示或暗示的任何未来结果、表现或成就存在重大差异。

Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist is developing obsolete or non-competitive; the ability to integrate and leverage artificial intelligence and machine learning technologies to improve operational efficiency, product development, and customer solutions; the ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist’s costs and delay commercialization efforts; changes in U.S.

此类风险和不确定性包括但不限于：吸引新客户以及保留并增加现有客户销售的能力；Twist实现足够收入以在任何特定期间实现或维持经营活动正现金流或盈利能力的能力；快速变化的技术和合成生物学领域激烈竞争的风险与不确定性，这可能使Twist正在开发的产品过时或失去竞争力；整合并利用人工智能和机器学习技术以提高运营效率、产品开发和客户解决方案的能力；扩展DNA合成生产能力的能力；对关键组件依赖单一供应商的风险；对关键人员的依赖；可能导致Twist成本增加并延迟商业化的额外法规；美国政策的变化。

trade policies and other trade actions that could result in increased costs and supply chain disruptions; the ability to mainta.

贸易政策和其他可能导致成本增加和供应链中断的贸易行动；维持能力。

For Investors:

对于投资者：

Angela Bitting

安吉拉·比廷

SVP, Corporate Affairs

高级副总裁，企业事务部

925-202-6211

abitting@twistbioscience.com

艾比汀@扭力生物科学.com

For Media: